COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
about
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reportsPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesNonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practiceRisk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsAn economic model of long-term use of celecoxib in patients with osteoarthritisFaecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes.Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.MedDRA® automated term groupings using OntoADR: evaluation with upper gastrointestinal bleedings.The challenges for cancer chemoprevention.Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores.Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis
P2860
Q24816687-12BAEA73-A77D-4FF6-B917-2BBB60AC10C6Q28200569-FC83D9C7-5DDB-4931-8966-4E28570976ABQ28200864-B8DC204B-173D-4AA5-A10C-5A1A3C1357E6Q28217824-F740405C-6D5B-44A2-9348-262D161DAC6BQ28218005-79FBF9D9-317A-465F-AAAA-D52821332365Q30481876-A04CFA82-70BB-406A-8357-0BF7E2886F17Q34310573-8205B072-0C79-4C85-8233-6351AB6E4D58Q36150589-AC82BE36-11A4-4C13-916B-5323060A6FF2Q38207875-CEAD40C5-C7D5-4440-A755-B2A5BD60AC5EQ38390830-E6407BF3-F73B-49CD-9999-CCB5B0B61174Q38643625-4D7E7530-DF6E-4E5C-A918-8B7F16E8E516Q53060894-80EE605E-4406-4B6D-8AE8-DC174A47E112Q57300657-8DB7B441-65A7-48E8-B7FD-BB0797905D96
P2860
COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
COX-2-selective inhibitors and ...... tion-based case-control study.
@en
COX-2-selective inhibitors and ...... tion-based case-control study.
@nl
type
label
COX-2-selective inhibitors and ...... tion-based case-control study.
@en
COX-2-selective inhibitors and ...... tion-based case-control study.
@nl
prefLabel
COX-2-selective inhibitors and ...... tion-based case-control study.
@en
COX-2-selective inhibitors and ...... tion-based case-control study.
@nl
P2093
P2860
P1476
COX-2-selective inhibitors and ...... tion-based case-control study.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2004.01913.X
P407
P577
2004-04-01T00:00:00Z